Research peptide · CJC-1295 ohne DAC / Ipamorelin
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
No reviews yet. Be the first to share your experience.
Research Use Only (RUO)
Tier I · Synthesis QC
Tier I · Synthesis QC
In-house · per step
RP-HPLC, MS confirmation, sequence verification in cleanroom.
Tier II · In-process
Tier II · In-process
Batch · final
Identity, purity, and assay before release.
Tier III · Third-party lab
Tier III · Third-party lab
External · independent
HPLC, ICP-MS, and microbiology by accredited lab.
953
satisfied
99.41%
Avg. purity 2026
4.8 ★
Store rating
| Designation | CJC-1295 No DAC + Ipamorelin |
| Components | Mod GRF 1-29 (No DAC) and Ipamorelin |
| Form | Shared lyophilized powder |
| Strength per vial | 5 mg CJC-1295 No DAC + 5 mg Ipamorelin |
| Box contents | 10 vials with identical composition |
| Total peptide per box | 50 mg + 50 mg |
| Purity | ≥99 % (HPLC) per component |
CJC-1295 without DAC matches the shortened GHRH sequence (Mod GRF 1-29) and activates the GHRH receptor. Ipamorelin is a selective agonist at the growth hormone secretagogue receptor (GHS-R). The combination places both ligands in a fixed ratio, so a laboratory can prepare concentration series for parallel or synchronous activation of both axes without merging two separate solutions. Teams that buy CJC-1295 Ipamorelin receive both peptides together, 5 mg of each per vial. The shared powder keeps the 1:1 mass relation intact from the first dilution through later working solutions, which keeps receptor comparisons on the same material lot.
The lyophilizate is reconstituted in the laboratory with a suitable sterile solvent. The solvent is added slowly along the vessel wall, and the preparation is mixed gently until the powder has dissolved completely. The solution is processed promptly and kept away from direct light until use. Volume and target concentration are set by the laboratory in its own protocol. Because both peptides leave the vial together, one dissolution step yields a stock that already carries the specified ratio for GHRH-R and GHS-R work.
In binding and functional assays the blend serves as a dual reference for GHRH-R and GHS-R. cAMP assays and calcium flux measurements can record both signalling pathways side by side. Cell models of somatotroph lines use the fixed dose relation to map interactions between the GHRH pathway and the ghrelin pathway under defined conditions. The shared lyophilized form simplifies identical dilution series across several experimental days and supports comparison with single peptide controls run from the same nominal masses.
Each lot is tested by HPLC for purity, and the result is ≥99 % for both peptides. Identity checks confirm the Mod GRF 1-29 sequence and the Ipamorelin pentapeptide. The findings are recorded per lot and apply uniformly to every vial in the box. That record gives a stable basis for reproducible in-vitro series and for side by side comparison with single peptide controls prepared at the same 5 mg scale.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.41% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
Ten vials with identical contents. Per vial: CJC-1295 No DAC 5 mg + Ipamorelin 5 mg. Per box: CJC-1295 No DAC 50 mg + Ipamorelin 50 mg.
No. All ten vials are unlabelled. Product identification appears exclusively on the outer kit packaging.
The labelled single vial in the product image is illustrative. The same image is used for all strengths of this product; your selected variant determines the contents.
For research use only. Not for human or animal use, diagnosis, therapy or consumption.
5-Amino-1MQ
AHK-Cu
AOD-9604
B12
BAC Water 10 ml
BPC-157
Cagrilintide 5 mg
CJC-1295 (Mod GRF 1-29)
